About this Research Topic
Glioblastoma (GBM) is the most common and aggressive malignant brain tumor in adults, with an extremely poor prognosis. Current treatment options at diagnosis are multimodal and include surgical resection, radiation, and chemotherapy. Despite aggressive resection and combined modality adjuvant treatment, most GBMs recur. Immunotherapy including immune checkpoint blockade, chimeric antigen receptor T (CAR T) cell therapy, oncolytic virotherapy, and vaccine therapy have offered new arms for improving GBM outcomes; In addition, it is now clear that GBM cells can influence the tumor microenvironment, which in turn acquires immunosuppressive properties and further facilitates the tumor growth. This is facilitated by the extreme plasticity of both GBM and immunosuppressive cells, which exist in several states and can rapidly switch to a different one upon the presence of stimuli such as cytokines and chemokines secreted in the tumor milieu.
Therefore, the identification of mechanisms contributing to the immunosuppressive microenvironment of GBM paves the way for the identification of potential targets to augment the antitumor immune responses.
This Research Topic will focus on the role of tumor microenvironment as critical regulator of cancer progression as well as on the status of preclinical and clinical trials, mainly focusing on the challenges and future perspectives in glioblastoma immuno-oncology.
Specifically, this topic will include:
• Studies on novel immunotherapeutic delivery approaches (i.e. studies on novel oncolytic virotherapy, vaccine, and CAR T cells)
• Studies on the investigation of checkpoint inhibitors.
Moreover, the topic will cover:
• Studies aimed at the identification and characterization of signaling mechanisms involved in the reprogramming of immunosuppressive cells (i.e.tumor-associated macrophages and regulatory T cells), which ultimately affect GBM progression.
This Research Topic includes basic science and clinical studies; we welcome high-quality original research articles, brief reports, and review articles.
Manuscripts including bioinformatics or computational analysis of public genomic or transcriptomic databases, should be accompanied by validation with clinical cohorts or corroborated by in vitro or in vivo experiments.
Therefore, the identification of mechanisms contributing to the immunosuppressive microenvironment of GBM paves the way for the identification of potential targets to augment the antitumor immune responses.
This Research Topic will focus on the role of tumor microenvironment as critical regulator of cancer progression as well as on the status of preclinical and clinical trials, mainly focusing on the challenges and future perspectives in glioblastoma immuno-oncology.
Specifically, this topic will include:
• Studies on novel immunotherapeutic delivery approaches (i.e. studies on novel oncolytic virotherapy, vaccine, and CAR T cells)
• Studies on the investigation of checkpoint inhibitors.
Moreover, the topic will cover:
• Studies aimed at the identification and characterization of signaling mechanisms involved in the reprogramming of immunosuppressive cells (i.e.tumor-associated macrophages and regulatory T cells), which ultimately affect GBM progression.
This Research Topic includes basic science and clinical studies; we welcome high-quality original research articles, brief reports, and review articles.
Manuscripts including bioinformatics or computational analysis of public genomic or transcriptomic databases, should be accompanied by validation with clinical cohorts or corroborated by in vitro or in vivo experiments.
Keywords: Glioblastoma, immunotherapy, oncogenes, tumor suppressor genes, microglia
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
